Company: EDSA
Filing Date: 2025-09-09
Form Type: 424B5
Source: 0001171843-25-005799
Chunk: 34

Company: Edesa Biotech, Inc.
Filing Date: 2025-09-09
Form: 424B5
Chunk 34
---
 agreement and this prospectus supplement and the accompanying prospectus, we may issue and sell from time to time
our common shares having an aggregate offering price of up to $4,006,544 through Wainwright as our sales agent or principal. As of September
9, 2025, we have issued and sold an aggregate of 304,057 of our common shares for gross proceeds of $837,134 pursuant to the Sales Agreement
and the related prospectus supplement, dated October 4, 2024 to the Company’s Registration Statement on Form S-3 (333-266604). Sales
of the common shares, if any, will be made by any method permitted by law deemed to be an “at-the-market offering” as defined
in Rule 415(a)(4) promulgated under the Securities Act, including sales made directly on or through the Nasdaq Capital Market, the existing
trading market for our common shares, or any other existing trading market in the United States for our common shares, sales made to or
through a market maker other than on an exchange or otherwise, directly to Wainwright as principal, in negotiated transactions at market
prices prevailing at the time of sale or at prices related to such prevailing market prices, and/or in any other method permitted by law.
If we and Wainwright agree on any method of distribution other than sales of our common shares into Nasdaq or another existing trading
market in the United States at market prices, we will file a further prospectus supplement providing all information about such offering
as required by Rule 424(b) under the Securities Act.

Wainwright will offer our common shares
at prevailing market prices subject to the terms and conditions of the Sales Agreement as agreed upon by us and Wainwright. We will designate
the number of shares which we desire to sell, the time period during which sales are requested to be made, any limitation on the number
of shares that may be sold in one day and any minimum price below which sales may not be made. Subject to the terms and conditions of
the Sales Agreement, Wainwright will use its commercially reasonable efforts consistent with its normal trading and sales practices and
applicable law and regulations to sell on our behalf all of the common shares requested to be sold by us. We or Wainwright may suspend
the offering of the common shares being made through Wainwright under the Sales Agreement upon proper notice to the other party and pursuant
to the terms of the Sales Agreement.